BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20230483)

  • 1. Growth and progression of melanoma and non-melanoma skin cancers regulated by ubiquitination.
    Nakayama K
    Pigment Cell Melanoma Res; 2010 Jun; 23(3):338-51. PubMed ID: 20230483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Greater expression of TC21/R-ras2 in highly aggressive malignant skin cancer.
    Lee JH; Pyon JK; Lee SH; Lee YJ; Kang SG; Kim CH; Kim DW; Nam HS; Park YH; Jeong DJ; Cho MK
    Int J Dermatol; 2011 Aug; 50(8):956-60. PubMed ID: 21781067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High numbers of human skin cancers express MMP2 and several integrin genes.
    Orimoto AM; Neto CF; Pimentel ER; Sanches JA; Sotto MN; Akaishi E; Ruiz IR
    J Cutan Pathol; 2008 Mar; 35(3):285-91. PubMed ID: 18251742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical galectin-3 expression in non-melanoma skin cancers.
    Kapucuoglu N; Basak PY; Bircan S; Sert S; Akkaya VB
    Pathol Res Pract; 2009; 205(2):97-103. PubMed ID: 18951731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant melanoma and nonmelanoma skin cancers in Northrhine-Westphalia, Germany: a patient- vs. diagnosis-based incidence approach.
    Stang A; Ziegler S; Büchner U; Ziegler B; Jöckel KH; Ziegler V
    Int J Dermatol; 2007 Jun; 46(6):564-70. PubMed ID: 17550552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of other cancers among patients with prior basal cell and squamous cell skin cancer.
    Karagas MR; Greenberg ER; Mott LA; Baron JA; Ernster VL
    Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):157-61. PubMed ID: 9488591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of metastasis.
    Nguyen TH
    Clin Dermatol; 2004; 22(3):209-16. PubMed ID: 15262306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleolar organizer region staining patterns in paraffin-embedded tissue cells from human skin cancers.
    Romão-Corrêa RF; Maria DA; Soma M; Sotto MN; Sanches JA; Neto CF; Ruiz IR
    J Cutan Pathol; 2005 May; 32(5):323-8. PubMed ID: 15811115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin.
    Sakiz D; Turkmenoglu TT; Kabukcuoglu F
    Pathol Res Pract; 2009; 205(9):589-94. PubMed ID: 19577853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical markers and driving mechanisms in melanoma progression: VEGF-C, RhoC, c-Ski/SnoN and EGFR.
    Boone B; Brochez L
    Verh K Acad Geneeskd Belg; 2009; 71(5):251-94. PubMed ID: 20232784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-melanoma skin cancer: what drives tumor development and progression?
    Boukamp P
    Carcinogenesis; 2005 Oct; 26(10):1657-67. PubMed ID: 15905207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that dysregulated DNA mismatch repair characterizes human nonmelanoma skin cancer.
    Young LC; Listgarten J; Trotter MJ; Andrew SE; Tron VA
    Br J Dermatol; 2008 Jan; 158(1):59-69. PubMed ID: 17970804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
    O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
    Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic analysis of the p53 gene in non-melanoma skin cancer and correlation with apoptosis and cell proliferation.
    Stratigos AJ; Kapranos N; Petrakou E; Anastasiadou A; Pagouni A; Christofidou E; Petridis A; Papadopoulos O; Kokka E; Antoniou C; Georgala S; Katsambas AD
    J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):180-6. PubMed ID: 15752287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas.
    Conscience I; Jovenin N; Coissard C; Lorenzato M; Durlach A; Grange F; Birembaut P; Clavel C; Bernard P
    Eur J Dermatol; 2006; 16(5):518-22. PubMed ID: 17101472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage.
    Baruthio F; Quadroni M; Rüegg C; Mariotti A
    Proteomics; 2008 Nov; 8(22):4733-47. PubMed ID: 18942674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
    Stoebner PE; Le Gallic L; Berthe ML; Boulle N; Lallemant B; Marque M; Gaspard C; Delfour C; Lavabre-Bertrand T; Martinez J; Meunier L
    Exp Dermatol; 2008 Nov; 17(11):908-15. PubMed ID: 18341568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes from skin screening clinics within a community-based melanoma screening program.
    Aitken JF; Janda M; Elwood M; Youl PH; Ring IT; Lowe JB
    J Am Acad Dermatol; 2006 Jan; 54(1):105-14. PubMed ID: 16384764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutations in human skin cancers.
    Giglia-Mari G; Sarasin A
    Hum Mutat; 2003 Mar; 21(3):217-28. PubMed ID: 12619107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression.
    Lee C; Ramirez JA; Guitart J; Diaz LK
    J Cutan Pathol; 2008 Nov; 35(11):989-94. PubMed ID: 18537861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.